Jerrold B. Grossman, a director at ADMA Biologics (NASDAQ:ADMA), purchased 12,500 shares of common stock on May 12, 2026, in an open market transaction. The shares were acquired at $8.01 each, totaling $100,125.
The stock is trading near its 52-week low of $7.21, down 53% year-to-date. According to Bond.az analysis, ADMA appears undervalued at current levels.
Following this purchase, Grossman directly holds 513,884 shares, consisting of 503,194 common shares and 10,690 restricted stock units (RSUs). Half of the RSUs vest on August 9, 2026, and the remaining half on February 9, 2027.
Grossman also indirectly owns shares through Brookwood LLC (22,857 shares), the Jerrold Grossman 2019 Irrevocable Trust (31,381 shares), Genesis Foundation Inc. (38,294 shares), and his spouse (175 shares).
In other news, ADMA Biologics reported Q1 2026 earnings of $0.19 per share, missing the $0.20 consensus estimate. Revenue was $114.5 million, below the expected $142.74 million.